Suppr超能文献

日本婴幼儿惊厥性癫痫持续状态的治疗

Treatment of convulsive status epilepticus in infants and young children in Japan.

作者信息

Sugai K

机构信息

Department of Child Neurology, National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan.

出版信息

Acta Neurol Scand. 2007 Apr;115(4 Suppl):62-70. doi: 10.1111/j.1600-0404.2007.00811.x.

Abstract

We review the types and causes of convulsive status epilepticus (CSE) in infants and young children in Japan, and discuss the current recommendations for the use of intravenous (IV) drugs in managing this condition, and report on our clinical experiences. There are prolonged or continuous CSE and clustered or intermittent CSE, and treatments are different between them. In Japan, fosphenytoin and IV preparation of lorazepam and phenobarbital are not available. Recently, midazolam and lidocaine (LDC) have been widely used, although neither of these drugs have official approval for the management of CSE. Febrile seizures and epilepsies are common causes of CSE in infants and young children in Japan, followed by benign infantile convulsions (BIC), convulsions with gastroenteritis (CwG), and acute encephalitis with refractory CSE and intractable epilepsy (AECSEE), which are familiar disorders in Japan. BIC and CwG frequently present with clustered CSE and do not respond to IV diazepam, but have an excellent response with oral carbamazepine or IV LDC. CSE in AECSEE requires control with barbiturate coma. The Research Committee on Clinical Evidence of Medical Treatment for Status Epilepticus in Childhood has developed a proposed guideline for the treatment of CSE in childhood in Japan by an evidence-based approach and consensus conference. Initial management of seizures should be attempted mainly with IV diazepam, the second-line treatment involves IV midazolam followed by IV phenytoin if seizures persist, and the third-line treatment requires barbiturate coma. However, our experience of 247 episodes of CSE in 77 patients, predominantly with chronic epilepsy, required different second-line treatments for prolonged CSE compared with clustered CSE: the former were treated with IV midazolam or pentobarbital, and the latter were given IV phenytoin or LDC. We propose modifications to the guideline for CSE that the second-line treatment is divided by prolonged CSE and clustered CSE, and that the procedures for brain protection and systemic management are added.

摘要

我们回顾了日本婴幼儿惊厥性癫痫持续状态(CSE)的类型和病因,讨论了目前用于治疗该病症的静脉注射(IV)药物的建议,并报告了我们的临床经验。CSE 有持续性或连续性 CSE 以及成簇性或间歇性 CSE,它们的治疗方法有所不同。在日本,磷苯妥英、劳拉西泮静脉制剂和苯巴比妥均无法获取。最近,咪达唑仑和利多卡因(LDC)已被广泛使用,尽管这两种药物均未获得用于治疗 CSE 的官方批准。发热性惊厥和癫痫是日本婴幼儿 CSE 的常见病因,其次是良性婴儿惊厥(BIC)、伴有肠胃炎的惊厥(CwG)以及伴有难治性 CSE 和难治性癫痫的急性脑炎(AECSEE),这些在日本都是常见病症。BIC 和 CwG 常表现为成簇性 CSE,对静脉注射地西泮无反应,但对口服卡马西平或静脉注射 LDC 反应良好。AECSEE 中的 CSE 需要通过巴比妥类昏迷进行控制。儿童癫痫持续状态医学治疗临床证据研究委员会已通过循证方法和共识会议制定了日本儿童 CSE 治疗的拟议指南。癫痫发作的初始管理应主要尝试使用静脉注射地西泮,二线治疗包括静脉注射咪达唑仑,如果癫痫发作持续则随后使用静脉注射苯妥英,三线治疗需要巴比妥类昏迷。然而,我们对 77 例患者共 247 次 CSE 发作的经验(主要为慢性癫痫患者)表明,与成簇性 CSE 相比,持续性 CSE 需要不同的二线治疗:前者用静脉注射咪达唑仑或戊巴比妥治疗,后者给予静脉注射苯妥英或 LDC。我们建议对 CSE 指南进行修改,将二线治疗按持续性 CSE 和成簇性 CSE 进行划分,并增加脑保护和全身管理的程序。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验